Detailed information for compound 1780095
Basic information
Technical information
- Name: Unnamed compound
- MW: 317.148 | Formula: C15H20BN3O4
-
H donors: 3
H acceptors: 5
LogP: 0.52
Rotable bonds: 7
Rule of 5 violations (Lipinski): 1 - SMILES: OB([C@@H](NC(=O)Cn1ccc2c(c1=O)cccn2)CC(C)C)O
- InChi: 1S/C15H20BN3O4/c1-10(2)8-13(16(22)23)18-14(20)9-19-7-5-12-11(15(19)21)4-3-6-17-12/h3-7,10,13,22-23H,8-9H2,1-2H3,(H,18,20)/t13-/m0/s1
- InChiKey: YVMYATWMIRGYBP-ZDUSSCGKSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | proteasome (prosome, macropain) subunit, beta type, 5 | Starlite/ChEMBL | References |
| Homo sapiens | proteasome (prosome, macropain) subunit, beta type, 1 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium falciparum | proteasome subunit alpha type-5, putative | proteasome (prosome, macropain) subunit, beta type, 5 | 160 aa | 148 aa | 23.0 % |
| Plasmodium falciparum | proteasome subunit beta type-5 | proteasome (prosome, macropain) subunit, beta type, 1 | 241 aa | 194 aa | 27.3 % |
Obtained from network model
Ranking Plot
Putative Targets List
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Inhibition (binding) | Inhibition of trypsin-like activity of 20S proteasome in human erythrocytes using Boc-Leu-Arg-Arg-AMC as substrate by fluorescence assay | ChEMBL. | 24946214 | |
| Inhibition (binding) | Inhibition of human 20S proteasome trypsin like activity using Boc-Leu-Leu-Arg-Arg-AMC as substrate at 20 uM measured over 10 mins by fluorescence assay | ChEMBL. | 23639651 | |
| Inhibition (binding) | > 40 % | Inhibition of human 20S proteasome chymotrypsin like activity using Suc-Leu-Leu-Val-Tyr-AMC as substrate at 20 uM measured over 10 mins by fluorescence assay relative to control | ChEMBL. | 23639651 |
| Inhibition (binding) | = 100 % | Inhibition of chymotrypsin-like activity of human 20S proteasome beta 5 subunit assessed as Suc-Leu-Leu-Val-Tyr-AMC substrate hydrolysis at 20 uM after 10 mins by fluorometric analysis | ChEMBL. | 24561716 |
| Ki (binding) | Inhibition of bovine pancreatic alpha-chymotrypsin using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence assay | ChEMBL. | 24946214 | |
| Ki (binding) | = 0.44 uM | Inhibition of human 20S proteasome chymotrypsin like activity using Suc-Leu-Leu-Val-Tyr-AMC as substrate measured over 10 mins by fluorescence assay | ChEMBL. | 23639651 |
| Ki (binding) | = 0.44 uM | Inhibition of chymotrypsin-like activity of human 20S proteasome beta 5 subunit assessed as Suc-Leu-Leu-Val-Tyr-AMC substrate hydrolysis after 10 mins by fluorometric analysis | ChEMBL. | 24561716 |
| Ki (binding) | = 0.44 uM | Inhibition of chymotrypsin-like activity of 20S proteasome in human erythrocytes using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence assay | ChEMBL. | 24946214 |
| Ki (binding) | = 1.55 uM | Inhibition of human 20S proteasome post-glutamyl peptide hydrolyzing activity using Z-Leu-Leu-Glu-AMC as substrate measured over 10 mins by fluorescence assay | ChEMBL. | 23639651 |
| Ki (binding) | = 1.55 uM | Inhibition of PGPH-like activity of 20S proteasome in human erythrocytes using Z-Leu-Leu-Glu-AMC as substrate by fluorescence assay | ChEMBL. | 24946214 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL2385817
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.